Estimation of once-daily amikacin dose in critically ill adults

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F18%3A10376634" target="_blank" >RIV/00216208:11110/18:10376634 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.1080/1120009X.2017.1376818" target="_blank" >https://doi.org/10.1080/1120009X.2017.1376818</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/1120009X.2017.1376818" target="_blank" >10.1080/1120009X.2017.1376818</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Estimation of once-daily amikacin dose in critically ill adults

Popis výsledku v původním jazyce

This study aimed at investigating variables affecting amikacin pharmacokinetics in order to propose optimal initial dosing in critically ill adult patients treated with once-daily amikacin regimen. Amikacin pharmacokinetics was calculated based on plasma concentrations using one compartmental analysis. Relationships between pharmacokinetic parameters and demographic/clinical data were explored in linear regression models. Simulated dose and dosing intervals were derived from body size descriptors and estimated creatinine clearances for each patient. Amikacin volume of distribution best correlated with body surface area, while amikacin clearance was best predicted by CKD-EPI creatinine clearance. Our study suggests that dose of 517 mg per m(2) of body surface area leads to amikacin levels most approaching target peak concentration. Dosing interval calculated as 228.7 x e(-3.08 x) (CKD-EPI) (creatinine clearance) ((mL s-1)) + 15.84 most closely approximated optimal dosing intervals based on individual pharmacokinetics. The dosing nomogram based on CKD-EPI creatinine clearance was designed.

Název v anglickém jazyce

Estimation of once-daily amikacin dose in critically ill adults

Popis výsledku anglicky

This study aimed at investigating variables affecting amikacin pharmacokinetics in order to propose optimal initial dosing in critically ill adult patients treated with once-daily amikacin regimen. Amikacin pharmacokinetics was calculated based on plasma concentrations using one compartmental analysis. Relationships between pharmacokinetic parameters and demographic/clinical data were explored in linear regression models. Simulated dose and dosing intervals were derived from body size descriptors and estimated creatinine clearances for each patient. Amikacin volume of distribution best correlated with body surface area, while amikacin clearance was best predicted by CKD-EPI creatinine clearance. Our study suggests that dose of 517 mg per m(2) of body surface area leads to amikacin levels most approaching target peak concentration. Dosing interval calculated as 228.7 x e(-3.08 x) (CKD-EPI) (creatinine clearance) ((mL s-1)) + 15.84 most closely approximated optimal dosing intervals based on individual pharmacokinetics. The dosing nomogram based on CKD-EPI creatinine clearance was designed.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30104 - Pharmacology and pharmacy

Projekt

—

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Chemotherapy

ISSN

1120-009X

e-ISSN

—

Svazek periodika

30

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

7

Strana od-do

37-43

Kód UT WoS článku

000428154600005

EID výsledku v databázi Scopus

2-s2.0-85030172217